Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients

Transplantation

Volumn 90, Issue 11, 2010, Pages 1215-1219

  Husain, Shahid ^a,b   Capitano, Blair ^c,d   Corcoran, Timothy ^a   Studer, Sean M ^a,e   Crespo, Maria ^a   Johnson, Bruce ^a   Pilewski, Joseph M ^a   Shutt, Kathleen ^a   Pakstis, Diana L ^a   Zhang, Shimin ^c   Carey, Mary Ellen ^a   Paterson, David L ^a,f   McCurry, Kenneth R ^c,g   Venkataramanan, Raman ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d PFIZER INC   (United States)

^e NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^f Queensland State Laboratory   (Australia)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aerosol Amphotericin B; Lung transplant recipients; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADULT; AEROSOL; ARTICLE; ASPERGILLUS; BRONCHOSPASM; CHILL; COUGHING; DIZZINESS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INVASIVE ASPERGILLOSIS; LUNG ALVEOLUS EPITHELIUM; LUNG LAVAGE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEBULIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TANDEM MASS SPECTROMETRY; TASTE; WHEEZING;

ADMINISTRATION, INHALATION; AEROSOLS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY MUCOSA; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

EID: 78650311259     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f995ea     Document Type: Article

References (20)

1. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160.
2. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
3. Allen SD, Sorensen KN, Nejdl MJ, et al. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungi-zone) amphotericin B in murine pulmonary aspergillosis. J Antimi-crob Chemother 1994; 34: 1001.
4. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations asprophylaxisof invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999; 93: 3654.
5. Drew RH, Dodds AE, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77: 232.
6. Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006; 6: 2765.
7. Gonda I. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst 1990; 6: 273.
8. Lasic DD, Papahadjopoulos D. Liposomes revisited. Science 1995; 267: 1275.
9. Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001; 72: 545.
10. Monforte V, Roman A, Gavalda J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation 2003; 75: 1571.
11. Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12: 631, viii.
12. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532.
13. AdedoyinA,Swenson CE, Bolcsak LE,et al.Apharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Che-mother 2000; 44: 2900.
14. Amantea MA, Bowden RA, Forrest A, et al. The population pharmaco-kinetics of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Chemotherapy 1999; 45(suppl 1): 48.
15. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 259.
16. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 2005; 43: 5243.
17. Monforte V, Ussetti P, Lopez R, et al. Nebulized liposomal amphoter-icin B prophylaxis for Aspergillus infection in lung transplantation: Pharmacokinetics and safety. J Heart Lung Transplant 2009; 28: 170.
18. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327.
19. Lee JW, Petersen ME, Lin P, et al. Quantitation of free and total am-photericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method. Ther Drug Monit 2001; 23: 268.
20. Lambros MP, Abbas SA, Bourne DW. New high-performance liquid chromatographic method for amphotericinBanalysis usinganinternal standard. J Chromatogr B Biomed Appl 1996; 685: 135.